• SRPT Small Trial With Big Promise!

    By Terry Chrisomalis - February 11, 2013 | Tickers: NVS, SRPT

    Awhile ago Sarepta Therapeutics (NASDAQ: SRPT) posted some amazing results on it's lead drug Eteplirsen! This drug compounds showed to restore protein in certain parts of the body that allowed patients suffering from a rare disease, known as muscular dystrophy, to be able to get stronger in movement function. The stock had done a reverse split prior to this announcement and then the big run up started for the more »

  • Hedge Funds are Interested in Arena Pharmaceuticals

    By Michael Meyer - January 16, 2013 | Tickers: ARNA, OREX, VVUS

    One of the ways that retail investors can even out the flow of information is by following what hedge funds are investing in. A popular way to do this is to follow the 13F reports that hedge funds file each quarter. And while just blindly following what the big funds are buying is probably not the best idea, making this strategy one of your criteria for investing might be a more »

  • 6 Biotechnology Stocks With Upcoming Catalysts

    By Michael Meyer - January 11, 2013 | Tickers: ARNA, CELG, CLSN, DNDN, JNJ, SNY, THLD

    Biotechnology can be one of the most volatile industries to be invested in.  A lot of the time, investors can own shares in various companies and not even know there is an event coming up.  This article will serve to inform investors of 6 biotechnology stocks that have upcoming catalysts in 2013.  These catalysts are likely to have a significant impact upon each company.

    1) Celsion Corporation (NASDAQ: CLSN)

    Celsion more »

  • Celldex May Soar in 2013

    By Michael Meyer - January 10, 2013 | Tickers: CLDX, SGEN

    With so many companies claiming to have found the miracle cure for all diseases, it can be a tough challenge to find the contenders instead of the pretenders.  But there is one company that appears to be getting closer to find the illusive treatment for breast cancer.  That company is Celldex Therapeutics (NASDAQ: CLDX).

    Celldex Therapeutics is a biopharmaceutical company focused on the development, manufacture, and commercialization of novel therapeutics more »

  • Arena's Short Interest Continues To Be Held At Bay While Fundamentals Play Out

    By Joseph Dedvukaj - December 17, 2012 | Tickers: ARNA

    Arena (NASDAQ: ARNA) short interest has grown to a peak of 61,748,793 shares on Nov 15 2012. Followed by the most recent decline to 56,263,870. Some smart shorts exited their positions. A short squeeze can be deliberately induced by a hedge fund or institution at any moment. We savvy investors closely monitor the daily available to short box to determine whether or not shorts are having more »

  • The Looming EU Approval Makes Arena Pharmaceuticals Significantly Undervalued

    By Joseph Dedvukaj - December 13, 2012 | Tickers: ARNA, VVUS

    Arena's weight management drug Belviq has been approved by the FDA for marketing in the United States. A few weeks ago, I wrote an article detailing Arena's path to profitability. I remain optimistic about Arena's prospects for global success in the obesity market. One big reason is, as of the writing of this article, we have learned Arena (NASDAQ: ARNA) is getting closer to approval for its more »

  • Revlimid Ramp-Up, New Drug Launches Make Celgene a Buy

    By John Macris - November 28, 2012 | Tickers: CELG, CLVS, ONXX

    Celgene (NASDAQ: CELG) is a global biopharmaceutical company focused on treating cancer and immune-inflammatory related diseases. The Summit, New Jersey-based company was founded in 1986 and has grown to employ more than 4,500 people worldwide.

    Let’s evaluate Celgene’s business as it stands today before considering upcoming catalysts for the company in the next six to twelve months. With a market capitalization of approximately $33 billion, Celgene derives more »

  • What Investors Should Know And Do To Make Sure The Short Interest In Arena's Stock Is Playing By The Rules.

    By Joseph Dedvukaj - November 26, 2012 | Tickers: ARNA, BAC, BCS, SCHW, C, CS, DB, ETFC, GS, HBC, JPM, MFG, NES.DL, PJC, RBS, BA, TST, UBS, WFC

    1. Arena (NASDAQ: ARNA) short-sellers using illegal short and distort-

    As of November 15, 2012, Arena short interest is 61,748,793 shares. This is the highest it has ever been. How much of the short interest is illegal naked shorting? We believe its substantial. It is no secret Arena investors know illegal naked short selling and stock manipulation are being used to manipulate Arena's stock to some extent more »

  • Baxter Presents Strong Company For Investment

    By Arveal L Turner - October 16, 2012 | Tickers: ABT, BAX, DD

    Baxter International is a company in the pharmaceutical sector that deserves a good look for investment. The company offers stability, new product lines, diverse markets, company growth and working partnerships that create an investment climate that works. Baxter International was founded in 1931 as a medical company that produced IV solutions. Today it's diverse product line includes: medical devices, healthcare solutions, new medicines and clinical trials. It is headquartered more »

  • 3 Key Issues Spectrum Pharmaceuticals Must Address

    By Brian Nichols - October 10, 2012 | Tickers: QCOR, SPPI

    On Tuesday October 9 Spectrum Pharmaceuticals(NASDAQ: SPPI) CEO Dr. Rajesh “Raj” Shrotriya was presenting at the 11th Annual BIO Investor Forum to provide an overview of the company’s business strategy and commercial and development-stage programs. As an investor in this company, I must admit, that once I saw the press release that Raj would be giving yet another presentation I was trembling, because I knew that the last more »

  • Who Needs Fracking When You Have DNA?

    By Robert Zimmerman - October 6, 2012 | Tickers: AMRS, BP, COG, DD, SZYM

    Without a doubt, one of the biggest things to hit the US energy market is hydraulic fracturing.  This technology has allowed domestic oil and natural gas production to soar.  Investors in gas producers like Cabot Oil and Gas (NYSE: COG) have profited nicely from the development of so-called shale gas.  COG has risen from $15 to $43 in two years.  The company claims to have 14 of the top 20 more »

  • Biotech Industry On The Upswing

    By Sharmistha Banerjee - October 3, 2012 | Tickers: REGN, SNY, VRTX

    There’s a huge surge at a record-setting pace in biotech employment at hundreds of companies, a recent survey shows. It’s estimated the industrial biotechnology sector will create 100,000 jobs in the United States during the next five years. The survey shows that hiring demand over the next 12 months among these companies is expected to be strongest for molecular/cell biologists, chemists, chemical engineers, fermentation specialists and more »

  • A Foolish Questcor Call

    By Brian Nichols - September 30, 2012 | Tickers: QCOR, SPPI, UNH

    Over the last four years I have been one of the biggest supporters of Questcor Pharmaceuticals (NASDAQ: QCOR), owning the stock off and on throughout various points in time, and I would have never anticipated its 63% loss during the last two weeks. On September 19 the stock fell 48% after health insurer Aetna (AET) said that it would limit coverage on the company’s drug Acthar. And if that more »

  • Stem Cell Therapy—Breakthrough in Health Paradigm

    By Sharmistha Banerjee - September 25, 2012 | Tickers: NBS, OSIR, PSTI

    Far-reaching accomplishments in the biotechnology sector meet its most ambitious expectations, stem cell therapy. The birth of this new industry has boosted the enthusiasm and energy of investors and has brought unprecedented capability and optimistic predictions. New developments in regenerative medicine are bringing about exciting, novel approaches to create therapies for hard to treat diseases. The biotechnology industry has been soaring in 2012 as companies both large and small have more »

  • Spectacular Growth Prospects

    By Sharmistha Banerjee - September 18, 2012 | Tickers: ALXN, REGN, SPPI

    The biotechnology industry is fuelling mobility and economic growth and it is expected to show a strong upward momentum in the future. Many investors once considered biotech stocks untouchable, but all that is about to change.  

    Spectrum Pharmaceuticals (NASDAQ: SPPI) a small, fast growing company which has achieved almost quadruple its revenue is gradually getting its due recognition in the biotechnology industry. The strengths and opportunities outnumber the weaknesses and more »

  • A Fool's Look at Galena Biopharma's Rally

    By Natalie Dawahare - September 13, 2012 | Tickers: ARNA, GALE, PCYC, REGN

    Chances are, you’re aware of the astonishing gains that some of biotech’s darlings have produced in the first nine months of 2012. Perhaps it’s Arena Pharmaceuticals’ (NASDAQ: ARNA) 350% gain; maybe its Pharmacyclics’ (NASDAQ: PCYC) 330% return, or even Regeneron’s (NASDAQ: REGN) 170% return in 2012 that has caught your attention. But most likely, it hasn’t been Galena Biopharma (NASDAQ: GALE), a $125 million company more »

  • How Global Growth of Cancer Can Make You Money

    By Ron Chatterjee - August 28, 2012 | Tickers: ABT, BMY, JNJ, MELA, RHHBY

    That sounded to be rather rude, eh?

    But to be honest, cancer is one of the most feared diseases of all (A February 2011 study conducted by Harris Interactive for MetLife Foundation found that 41% of Americans shudder when they hear the word "cancer"). According to the National Institutes of Health (NIH), medical costs due to cancer in 2007 are reported at around $226.8 billion, and we have over more »

  • Bull Case for Mannkind

    By Krishna Maheshwari - May 24, 2012 | Tickers: ALKS, LLY, MNKD, NVO, PFE

    Mannkind (NASDAQ: MNKD) is a multi-bagger from its current levels in the next 1-3 years.

    This article will dive into the key elements of the investment thesis behind why I think Mannkind has such an enomous potential and will also highlight some of the risks.  As a summary, we have a serial entrepreneur with multiple successes in the CEO.  The drug has gone through Phase III clinical trials with no more »

  • Do You have Enough FUN in Your Portfolio?

    By Justin Carley - May 2, 2012 | Tickers: AMZN, BEAM

    With the warmest winter in a century now in the record books, it is time for investors to focus their attention on summer and let the optimism shine.  Or not, as we are constantly reminded about what transpired the previous two summers- European distress and a near 20% correction in equity markets.  And guess what, European data is weakening anew.  Do you sell in anticipation of a third consecutive summer flight to safety?  Do you remember the strong presidential election cycle track record for stocks and hold through any intermittent corrections, albeit with elevated stress levels?  My recommendation is that investors forget all this headline garbage and add an often overlooked component to their portfolio- FUN.  I use the term fun, but other synonyms are whim, prayer, homerun, and gut instinct. 

  • Amylin Ignites the Biotech Sector

    By Tony Daltorio - March 30, 2012 | Tickers: AMLN, AZN, BMY, LLY, SNY

    Word came out this week that Amylin Pharmaceuticals (NASDAQ: AMLN) turned down a $3.5 billion, $22 a share takeover offer from Bristol-Myers Sqiubb (NYSE: BMY). This rumored bid lit a fire under much of the biotechnology sector as the hopes of more acquisitions in the space was rekindled. According to Bloomberg, there have already been 16 acquisitions, valued at more than $1 billion each, in the sector over the more »

  • Page 1 of 2